Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient mapping and outcome after radiofrequency ablation

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 75-87

  Mori, Yoshiyuki ^a   Tamai, Hideyuki ^a   Shingaki, Naoki ^a   Moribata, Kosaku ^a   Deguchi, Hisanobu ^a   Ueda, Kazuki ^a   Inoue, Izumi ^a   Maekita, Takao ^a   Iguchi, Mikitaka ^a   Kato, Jun ^a   Terada, Masaki ^b   Ichinose, Masao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Wakayama Minami Radiology Clinic   (Japan)

Author keywords

Apparent diffusion coefficient map; Diffusion weighted imaging; Hepatocellular carcinoma; Magnetic resonance imaging; Radiofrequency ablation

Indexed keywords

AGED; ARTICLE; CANCER RECURRENCE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; RECURRENCE RISK; SURVIVAL RATE;

EID: 84921027796     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12311     Document Type: Article

References (42)

1. Shiina S, Tateishi R, Arano T etal. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-577; quiz 578.
2. Clinical Practice Guidelines for Hepatocellular Carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010; 40 (Suppl 1): 2-144.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
4. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
5. Nicoli N, Casaril A, Abu Hilal M etal. A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation. Am J Surg 2004; 188: 165-167.
6. Masuda T, Beppu T, Ishiko T etal. Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Surg 2008; 15: 589-595.
7. Mori Y, Tamai H, Shingaki N etal. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int 2009; 3: 509-515.
8. Seki T, Tamai T, Ikeda K etal. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001; 13: 291-294.
9. Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol 2003; 8: 332-335.
10. Portolani N, Tiberio GA, Ronconi M etal. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003; 50: 2179-2184.
11. Ruzzenente A, Manzoni GD, Molfetta M etal. Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation. World J Gastroenterol 2004; 10: 1137-1140.
12. Llovet JM, Vilana R, Bru C etal. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-1129.
13. Imamura J, Tateishi R, Shiina S etal. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008; 103: 3057-3062.
14. Shirai K, Tamai H, Shingaki N etal. Clinical features and risk factors of extrahepatic seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2011; 41: 738-745.
15. Kim SH, Lim HK, Choi D etal. Percutaneous radiofrequency ablation of hepatocellular carcinoma: effect of histologic grade on therapeutic results. AJR Am J Roentgenol 2006; 186: S327-333.
16. Okusaka T, Okada S, Ueno H etal. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002; 95: 1931-1937.
17. Fukuda S, Itamoto T, Nakahara H etal. Clinicopathologic features and prognostic factors of resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology 2005; 52: 1163-1167.
18. Imai K, Beppu T, Nakayama Y etal. Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. J Surg Oncol 2009; 100: 121-126.
19. Yamashita Y, Tsuijita E, Takeishi K etal. Predictors for microinvasion of small hepatocellular carcinoma
20. Heo SH, Jeong YY, Shin SS etal. Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor. Korean J Radiol 2010; 11: 295-303.
21. Nishie A, Tajima T, Asayama Y etal. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011; 80: e29-33.
22. Nakanishi M, Chuma M, Hige S etal. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 1302-1309.
23. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
24. Choi D, Lim HK, Rhim H etal. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17: 684-692.
25. Guglielmi A, Ruzzenente A, Sandri M etal. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg 2007; 11: 143-149.
26. Takahashi S, Kudo M, Chung H etal. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008; 75 (Suppl 1): 91-98.
27. Yan K, Chen MH, Yang W etal. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol 2008; 67: 336-347.
28. Izumi N, Asahina Y, Noguchi O etal. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer 2001; 91: 949-956.
29. Yamanaka Y, Shiraki K, Miyashita K etal. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. World J Gastroenterol 2005; 11: 2174-2178.
30. Zytoon AA, Ishii H, Murakami K etal. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 2007; 37: 658-672.
31. Harrison LE, Koneru B, Baramipour P etal. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003; 197: 759-764.
32. Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006; 59: 432-441.
33. Lam VW, Ng KK, Chok KS etal. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207: 20-29.
34. Fukuda S, Itamoto T, Amano H etal. Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg 2007; 31: 345-352.
35. Yu HC, Cheng JS, Lai KH etal. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol 2005; 11: 1439-1444.
36. Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. Liver Int 2009; 29: 443-448.
37. Yamamoto N, Okano K, Kushida Y, Deguchi A, Yachida S, Suzuki Y. Clinicopathology of recurrent hepatocellular carcinomas after radiofrequency ablation treated with salvage surgery. Hepatol Res 2013. [Epub ahead of print].
38. Sasaki M, Yamada K, Watanabe Y etal. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008; 249: 624-630.
39. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005; 22: 80-85.
40. Bonekamp S, Torbenson MS, Kamel IR. Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis. J Clin Gastroenterol 2011; 45: 885-892.
41. Bakan AA, Inci E, Bakan S, Gokturk S, Cimilli T. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis. Eur Radiol 2012; 22: 682-687.
42. Nasu K, Kuroki Y, Sekiguchi R, Kazama T, Nakajima H. Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis? Radiat Med 2006; 24: 438-444.